SINOVAC and Eurofarma Establish Strategic Vaccine Partnership in Brazil Witnessed by President Lula

BEIJING, May 13, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, announced the signing of a strategic vaccine cooperation agreement with Eurofarma, a leading Brazilian pharmaceutical company. The signing ceremony was witnessed by Brazilian President Luiz Inácio Lula da Silva.

Under the terms of the agreement, the two organizations will establish a Sino-Brazilian vaccine manufacturing platform. This initiative is designed to facilitate the localized production of various vaccines, targeting supply requirements for the Brazilian market and extending reach to other nations in the Global South.

Strengthening Public Health Infrastructure The signing was attended by high-level officials, including Brazil's Minister of Health, Alexandre Padilha; Chief of Staff, Rui Costa; and Minister of Foreign Affairs, Mauro Vieira. SINOVAC leadership present included Chairman, President, and CEO Weidong Yin; Vice President Weining Meng; and Director of International Organizations (LATAM), Cintia Lucci.

Minister Padilha noted the historical significance of the partnership, referencing SINOVAC's critical role in Brazil's pandemic response. He emphasized that the ongoing collaboration and SINOVAC's sustained investment in the region serve as a testament to the deepened technical and institutional trust between the two entities.

During the event, President Lula highlighted the strategic nature of the Brazil-China relationship, noting that China remains an essential partner. He welcomed the expansion of Chinese industrial and health-related investments within Brazil.

Commitment to Research and Regional Stability On May 13, a delegation led by Minister Padilha conducted a formal visit to the SINOVAC Vaccine Quality Research Center in Beijing for a technical tour and high-level exchange. The delegation was received by SINOVAC's executive leadership, including Chairman and CEO Weidong Yin. The visit focused on reviewing the milestones achieved through localized vaccine production in Brazil and the technical standards maintained across SINOVAC's research and manufacturing facilities.

SINOVAC's long-term strategy in Latin America is built on deep-tier partnerships in markets such as Brazil, Chile, and Colombia. These collaborations extend beyond supply to include vaccine R&D, clinical research, and the establishment of localized production capabilities. Notable examples include the joint research and manufacturing initiatives with the Butantan Institute in Brazil and the Pontifical Catholic University of Chile, which have positioned SINOVAC as a primary vaccine provider within the regional health ecosystem.

Long-term Outlook Internationalization remains a core component of SINOVAC's long-term growth strategy. By prioritizing Brazil and the wider Latin American region, the Company intends to transition from a supplier model to a deeply integrated partner, investing in frontier biotechnologies and broader healthcare infrastructure to support regional health security.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.